Propanc Biopharma, Inc. (Nasdaq: PPCB) entered into a service agreement with German contract development organization FyoniBio GmbH on March 10 2026 to develop and validate a liquid chromatography‑mass spectrometry (LC‑MS) pharmacokinetics (PK) assay for its lead candidate PRP.
Continue reading for full analysis...
Propanc Biopharma disclosed its half‑year financial results for the six months ended December 31, 2025, showing a cash balance of $561,237 and an accumulated deficit of $134.48 million. The figures reflect the company’s ongoing cash burn and the need for additional financing to support its clinical program.
Continue reading for full analysis...